Pharmaceutical

Alliance Pharma agrees to £362m acquisition by DBAY

The offer represents a 3.6% increase from the initial offer in January 2025, from 62.5 pence per share to 64.75 pence per share.

Mar 11, 2025 - 06:00
Alliance Pharma agrees to £362m acquisition by DBAY
The offer represents a 3.6% increase from the initial offer in January 2025, from 62.5 pence per share to 64.75 pence per share.
Read the original article

Tags:

Previous Article

Roche announces hub for cardiovascular, renal and metabolism research

Next Article

EC approves BMS’ Opdivo and Yervoy combo for HCC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of Approval

TNT-119 by Eliem Therapeutics for Membranous Glomerulon...

May 19, 2024

STAT+: Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows

STAT+: Longer treatment gave better liver outcomes for ...

Mar 4, 2024

Bluejay touts positive data for chronic hepatitis D treatment

Bluejay touts positive data for chronic hepatitis D tre...

Jun 6, 2024